Fabiola Terzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fabiola Terzi has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
Martine Burtin
Université Paris Cité, INSERM UMR-U1151, CNRS UMR-8253, Institut Necker Enfants Malades, Paris, France
11 shared publicationsClément Nguyen
INSERM UMR-U1151, CNRS UMR-8253, Institut Necker Enfants Malades, Université Paris Cité, Paris, France
10 shared publications- Frank Bienaimé
Université Paris Cité, Faculté de Médecine; AP-HP; Service de Physiologie Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France; Institut Necker Enfants Malades-INEM, Département Croissance et Signalisation', INSERM UMR1151, CNRS UMR 8253, Paris, France
7 shared publications - Gérard Friedlander
Weizmann Institute of Science
6 shared publications - Amandine Viau
INSERM U1163 - Institut IMAGINE
5 shared publications Denise Laouari
Université de Paris, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique UMR 8253, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Paris, France
5 shared publications
Latest Publications
- Open Access
A cilia-dependent inflammatory programme links bacterial detection to kidney disease
The primary cilium is a microtubule-based sensory organelle projecting from the plasma membrane of most mammalian cells. Genetic defects in ciliary components cause chronic kidney disease (CKD) characterized by heightened production of inflammatory and fibrogenic mediators by tubular epithelial cells. Yet, whether this reflects a physiological role of the primary cilium remains unknown. Here, we show that primary cilia on kidney tubular cells bind uropathogenic Escherichia coli and, in response to bacterial components, initiate a fibro-inflammatory program reminiscent of CKD. Integrating single-cell transcriptomics with conditional mouse models, we observed that epithelial cilia orchestrate a similar fibro-inflammatory response in the absence of infection during CKD. This convergence reveals a shared cilia-dependent signalling axis governing both host–pathogen responses and CKD progression. Mechanistically, cilia ablation selectively impairs tubular responses to ADP-heptose, a pathogen-associated molecular pattern that activates NF-κB via the cytosolic innate immune receptor ALPK1. In human kidney organoids, ADP-heptose induces robust fibro-inflammation, and genetic or pharmacological inhibition of ALPK1 attenuates this response in a rodent CKD model. Together, these findings identify primary cilia as central orchestrators of a fibro-inflammatory program linking pathogen detection to kidney disease progression.
Open AccessA cilia-dependent inflammatory programme links bacterial detection to kidney disease
The primary cilium is a microtubule-based sensory organelle projecting from the plasma membrane of most mammalian cells. Genetic defects in ciliary components cause chronic kidney disease (CKD) characterized by heightened production of inflammatory and fibrogenic mediators by tubular epithelial cells. Yet, whether this reflects a physiological role of the primary cilium remains unknown. Here, we show that primary cilia on kidney tubular cells bind uropathogenic Escherichia coli and, in response to bacterial components, initiate a fibro-inflammatory program reminiscent of CKD. Integrating single-cell transcriptomics with conditional mouse models, we observed that epithelial cilia orchestrate a similar fibro-inflammatory response in the absence of infection during CKD. This convergence reveals a shared cilia-dependent signalling axis governing both host–pathogen responses and CKD progression. Mechanistically, cilia ablation selectively impairs tubular responses to ADP-heptose, a pathogen-associated molecular pattern that activates NF-κB via the cytosolic innate immune receptor ALPK1. In human kidney organoids, ADP-heptose induces robust fibro-inflammation, and genetic or pharmacological inhibition of ALPK1 attenuates this response in a rodent CKD model. Together, these findings identify primary cilia as central orchestrators of a fibro-inflammatory program linking pathogen detection to kidney disease progression.
- Top Cited Papers
- 16 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6795) , eaea3219
HNF1B integrates signals in a feed-forward loop driving kidney disease progression
Chronic kidney disease (CKD), which affects more than 10% of the global population, may continue to progress even after the triggering insult has resolved, suggesting the involvement of self-sustaining mechanisms that remain poorly understood. Here, we identify this molecular circuitry, centered on the transcription factor HNF1B, a key regulator of renal epithelial identity. In adult kidneys, HNF1B loss disrupts epithelial differentiation and quiescence, induces replication stress, and triggers CKD. Conversely, CKD itself epigenetically suppresses HNF1B activity, creating a vicious cycle that amplifies disease progression. In a cohort of 900 patients, lower HNF1B activity correlated with greater CKD severity, linking this mechanism to common forms of the disease. These findings unify rare Mendelian and common complex kidney disorders and identify HNF1B loss as a driver of CKD.
- 16 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6795) , eaea3219
Top Cited PapersHNF1B integrates signals in a feed-forward loop driving kidney disease progression
Chronic kidney disease (CKD), which affects more than 10% of the global population, may continue to progress even after the triggering insult has resolved, suggesting the involvement of self-sustaining mechanisms that remain poorly understood. Here, we identify this molecular circuitry, centered on the transcription factor HNF1B, a key regulator of renal epithelial identity. In adult kidneys, HNF1B loss disrupts epithelial differentiation and quiescence, induces replication stress, and triggers CKD. Conversely, CKD itself epigenetically suppresses HNF1B activity, creating a vicious cycle that amplifies disease progression. In a cohort of 900 patients, lower HNF1B activity correlated with greater CKD severity, linking this mechanism to common forms of the disease. These findings unify rare Mendelian and common complex kidney disorders and identify HNF1B loss as a driver of CKD.
- Open Access
- 26 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1689-1703
Lipocalin-2 Is Induced by Uromodulin Aggregates without Affecting Kidney Disease Progression in Autosomal Dominant Tubulointerstitial Kidney Disease–U MOD
Key Points: Lipocalin-2 upregulation paralleled intracellular uromodulin aggregates in mouse and cellular models of autosomal dominant tubulointerstitial kidney disease because of pathogenic uromodulin. The induction of lipocalin-2 was triggered by mutant uromodulin accumulation and endoplasmic reticulum stress in tubular cells. Genetic loss of lipocalin-2 reduced iron deposits in the kidney but did not affect kidney damage, indicating that lipocalin-2 was not driving disease progression. Background: Autosomal dominant tubulointerstitial kidney disease due to pathogenic UMOD variants (ADTKD- UMOD ) is a toxic proteinopathy caused by intracellular accumulation of mutant uromodulin (UMOD) and endoplasmic reticulum (ER) stress. Lipocalin-2 (LCN2) is an acute phase protein induced by ER stress with context-dependent roles in kidney injury. Methods: To examine the role of LCN2 in ADTKD- UMOD , we used Umod knock-in mouse models (C171Y, R186S, C125R), urine samples from affected patients, and mIMCD3 cells expressing wild-type or mutant UMOD. LCN2 expression was assessed by immunoblotting, immunostaining, and ELISA. Autophagy was stimulated with Torin1 to evaluate effects on LCN2 induction. Umod R186S/+ mice were crossed with Lcn2 −/− mice to determine the impact of LCN2 deficiency on disease progression. Results: Robust LCN2 induction was observed in kidneys and urine of Umod R186S/+ , Umod C125R/+ , and Umod C171Y/+ mice, correlating with UMOD aggregates and ER stress severity in thick ascending limb cells. In patients, specific UMOD variants were associated with elevated urinary LCN2. In mIMCD3 cells expressing mutant UMOD (C170Y, R185S), treatment with Torin1 reduced aggregates and attenuated LCN2 induction. Genetic deletion of Lcn2 in Umod R186S/+ mice decreased interstitial iron deposition but did not alter UMOD accumulation, interstitial inflammation, or fibrosis. Conclusions: LCN2 was induced by intracellular UMOD aggregates and ER stress in various models of ADTKD- UMOD . Although it influenced iron handling, LCN2 did not drive fibrosis or inflammation, supporting a role as a biomarker of toxic proteinopathy rather than a therapeutic target.
- 26 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1689-1703
Open AccessLipocalin-2 Is Induced by Uromodulin Aggregates without Affecting Kidney Disease Progression in Autosomal Dominant Tubulointerstitial Kidney Disease–U MOD
Key Points: Lipocalin-2 upregulation paralleled intracellular uromodulin aggregates in mouse and cellular models of autosomal dominant tubulointerstitial kidney disease because of pathogenic uromodulin. The induction of lipocalin-2 was triggered by mutant uromodulin accumulation and endoplasmic reticulum stress in tubular cells. Genetic loss of lipocalin-2 reduced iron deposits in the kidney but did not affect kidney damage, indicating that lipocalin-2 was not driving disease progression. Background: Autosomal dominant tubulointerstitial kidney disease due to pathogenic UMOD variants (ADTKD- UMOD ) is a toxic proteinopathy caused by intracellular accumulation of mutant uromodulin (UMOD) and endoplasmic reticulum (ER) stress. Lipocalin-2 (LCN2) is an acute phase protein induced by ER stress with context-dependent roles in kidney injury. Methods: To examine the role of LCN2 in ADTKD- UMOD , we used Umod knock-in mouse models (C171Y, R186S, C125R), urine samples from affected patients, and mIMCD3 cells expressing wild-type or mutant UMOD. LCN2 expression was assessed by immunoblotting, immunostaining, and ELISA. Autophagy was stimulated with Torin1 to evaluate effects on LCN2 induction. Umod R186S/+ mice were crossed with Lcn2 −/− mice to determine the impact of LCN2 deficiency on disease progression. Results: Robust LCN2 induction was observed in kidneys and urine of Umod R186S/+ , Umod C125R/+ , and Umod C171Y/+ mice, correlating with UMOD aggregates and ER stress severity in thick ascending limb cells. In patients, specific UMOD variants were associated with elevated urinary LCN2. In mIMCD3 cells expressing mutant UMOD (C170Y, R185S), treatment with Torin1 reduced aggregates and attenuated LCN2 induction. Genetic deletion of Lcn2 in Umod R186S/+ mice decreased interstitial iron deposition but did not alter UMOD accumulation, interstitial inflammation, or fibrosis. Conclusions: LCN2 was induced by intracellular UMOD aggregates and ER stress in various models of ADTKD- UMOD . Although it influenced iron handling, LCN2 did not drive fibrosis or inflammation, supporting a role as a biomarker of toxic proteinopathy rather than a therapeutic target.
- 19 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1174-1190
Clustered Mitochondrial Homolog Inhibition by Lipocalin-2 Orchestrates Mitochondrial Disruption and Contributes to Kidney Disease
Key Points: Lipocalin-2 inhibited clustered mitochondrial homolog (CLUH) activity and caused mitochondrial dysfunction. Loss of CLUH in kidneys triggered metabolic reprogramming and impaired mitochondrial structure. CLUH expression decreased with kidney injury and correlated with kidney function decline in patients. Background: Lipocalin-2 (LCN2) is a secreted protein involved in transporting hydrophobic molecules, regulating antibacterial responses and iron homeostasis. LCN2 expression increases after kidney damage and participates in CKD onset. We previously identified LCN2 as a regulator of mitochondrial dysfunction in renal tubular cells. This study aims to better understand LCN2's role in mitochondrial dysfunction and kidney pathology. Methods: LCN2 interactome was studied using mass spectrometry. The impact of LCN2 on clustered mitochondrial homolog (CLUH) activity was explored by immunofluorescence, Western blot, quantitative PCR, and RNA-immunoprecipitation. The role of CLUH on mitochondrial function in kidney was evaluated by RNAseq, metabolomics, electron microscopy, and immunochemistry using transgenic mice. Results: We characterized LCN2 interactome and identified CLUH in a multiprotein complex with LCN2. CLUH regulates mitochondrial homeostasis by binding mRNAs of nuclear-encoded mitochondrial proteins and promoting their translation. We demonstrated that LCN2 inhibited CLUH activity, leading to perinuclear mitochondrial clustering. We showed that CLUH was expressed in renal tubular cells and that its expression and activity decreased, while LCN2 expression increased after kidney injury leading to CKD. In human CKD patients, CLUH expression was inversely correlated with kidney lesions and kidney failure. CLUH genetic deletion in kidney nephron induced mitochondrial dysfunction and a subsequent interstitial fibrosis and kidney loss of function. Conclusions: This study shows that LCN2 forms a complex with CLUH and inhibits its activity, leading to perinuclear mitochondrial clustering. CLUH loss of function in renal tubular cells is associated with mitochondrial dysfunction and fibrosis, and in humans, CLUH expression inversely correlates with kidney lesions and loss of function.
- 19 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1174-1190
Clustered Mitochondrial Homolog Inhibition by Lipocalin-2 Orchestrates Mitochondrial Disruption and Contributes to Kidney Disease
Key Points: Lipocalin-2 inhibited clustered mitochondrial homolog (CLUH) activity and caused mitochondrial dysfunction. Loss of CLUH in kidneys triggered metabolic reprogramming and impaired mitochondrial structure. CLUH expression decreased with kidney injury and correlated with kidney function decline in patients. Background: Lipocalin-2 (LCN2) is a secreted protein involved in transporting hydrophobic molecules, regulating antibacterial responses and iron homeostasis. LCN2 expression increases after kidney damage and participates in CKD onset. We previously identified LCN2 as a regulator of mitochondrial dysfunction in renal tubular cells. This study aims to better understand LCN2's role in mitochondrial dysfunction and kidney pathology. Methods: LCN2 interactome was studied using mass spectrometry. The impact of LCN2 on clustered mitochondrial homolog (CLUH) activity was explored by immunofluorescence, Western blot, quantitative PCR, and RNA-immunoprecipitation. The role of CLUH on mitochondrial function in kidney was evaluated by RNAseq, metabolomics, electron microscopy, and immunochemistry using transgenic mice. Results: We characterized LCN2 interactome and identified CLUH in a multiprotein complex with LCN2. CLUH regulates mitochondrial homeostasis by binding mRNAs of nuclear-encoded mitochondrial proteins and promoting their translation. We demonstrated that LCN2 inhibited CLUH activity, leading to perinuclear mitochondrial clustering. We showed that CLUH was expressed in renal tubular cells and that its expression and activity decreased, while LCN2 expression increased after kidney injury leading to CKD. In human CKD patients, CLUH expression was inversely correlated with kidney lesions and kidney failure. CLUH genetic deletion in kidney nephron induced mitochondrial dysfunction and a subsequent interstitial fibrosis and kidney loss of function. Conclusions: This study shows that LCN2 forms a complex with CLUH and inhibits its activity, leading to perinuclear mitochondrial clustering. CLUH loss of function in renal tubular cells is associated with mitochondrial dysfunction and fibrosis, and in humans, CLUH expression inversely correlates with kidney lesions and loss of function.
- Open Access
- 10 October 2025
- Published by EDP Sciences in médecine/sciences
- Vol. 41, 97-102
La maladie rénale chronique
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
- 10 October 2025
- Published by EDP Sciences in médecine/sciences
- Vol. 41, 97-102
Open AccessLa maladie rénale chronique
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
- 25 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (804) , eadq7825
Podocyte-specific YAP activation triggers crescentic glomerulonephritis through cross-talk with parietal epithelial cells
Crescentic glomerulonephritis (cGN) is a severe kidney pathology characterized by the aberrant proliferation of epithelial cells, leading to crescent formation within the Bowman’s space. The molecular pathways involved in crescent formation remain poorly understood despite its clinical relevance. Given the mechanical stress experienced by podocytes, likely exacerbated in cGN, we hypothesized that activation of the mechanosensor yes-associated protein 1 (YAP), an effector of the Hippo pathway, may contribute to the development of cGN. Here, we demonstrate activation of YAP and its target genes in the nephrotoxic nephritis model, a murine model of cGN. Mechanistically, podocyte-specific hyperactivation of YAP (YAP 5SA ) in transgenic mice led to cell-autonomous hypertrophy of podocytes and non–cell-autonomous activation and proliferation of parietal epithelial cells (PECs), culminating in crescents. Transcriptomic profiling in a human podocyte cell line expressing the same YAP 5SA isoform revealed the reactivation of developmental programs within differentiated podocytes and identified the phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin (PI3K-Akt-mTOR) signaling pathway as a candidate involved in YAP-induced podocyte hypertrophy. Furthermore, this analysis identified connective tissue growth factor (CTGF) and heparin-binding epidermal growth factor–like growth factor (HB-EGF) as potential mediators in the cross-talk between YAP-activated podocytes and PECs, driving PEC hyperplasia. Collectively, these findings highlight the pivotal role of YAP in the pathogenesis of cGN and indicate that targeting YAP signaling could be a promising therapeutic strategy for this severe kidney disease.
- 25 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (804) , eadq7825
Podocyte-specific YAP activation triggers crescentic glomerulonephritis through cross-talk with parietal epithelial cells
Crescentic glomerulonephritis (cGN) is a severe kidney pathology characterized by the aberrant proliferation of epithelial cells, leading to crescent formation within the Bowman’s space. The molecular pathways involved in crescent formation remain poorly understood despite its clinical relevance. Given the mechanical stress experienced by podocytes, likely exacerbated in cGN, we hypothesized that activation of the mechanosensor yes-associated protein 1 (YAP), an effector of the Hippo pathway, may contribute to the development of cGN. Here, we demonstrate activation of YAP and its target genes in the nephrotoxic nephritis model, a murine model of cGN. Mechanistically, podocyte-specific hyperactivation of YAP (YAP 5SA ) in transgenic mice led to cell-autonomous hypertrophy of podocytes and non–cell-autonomous activation and proliferation of parietal epithelial cells (PECs), culminating in crescents. Transcriptomic profiling in a human podocyte cell line expressing the same YAP 5SA isoform revealed the reactivation of developmental programs within differentiated podocytes and identified the phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin (PI3K-Akt-mTOR) signaling pathway as a candidate involved in YAP-induced podocyte hypertrophy. Furthermore, this analysis identified connective tissue growth factor (CTGF) and heparin-binding epidermal growth factor–like growth factor (HB-EGF) as potential mediators in the cross-talk between YAP-activated podocytes and PECs, driving PEC hyperplasia. Collectively, these findings highlight the pivotal role of YAP in the pathogenesis of cGN and indicate that targeting YAP signaling could be a promising therapeutic strategy for this severe kidney disease.
- Open Access
- 6 June 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (15)
PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis
Proliferative glomerulonephritis is a severe condition that often leads to kidney failure. There is a significant lack of effective treatment for these disorders. Here, following the identification of a somatic PIK3CA gain-of-function mutation in podocytes of a patient, we demonstrate using multiple genetically engineered mouse models, single-cell RNA sequencing, and spatial transcriptomics the crucial role played by this pathway for proliferative glomerulonephritis development by promoting podocyte proliferation, dedifferentiation, and inflammation. Additionally, we show that alpelisib, a PI3Kα inhibitor, improves glomerular lesions and kidney function in different mouse models of proliferative glomerulonephritis and lupus nephritis by targeting podocytes. Surprisingly, we determined that pharmacological inhibition of PI3Kα affects B and T lymphocyte populations in lupus nephritis mouse models, with a decrease in the production of proinflammatory cytokines, autoantibodies, and glomerular complement deposition, which are all characteristic features of PI3Kδ inhibition, the primary PI3K isoform expressed in lymphocytes. Importantly, PI3Kα inhibition does not impact lymphocyte function under normal conditions. These findings were then confirmed in human lymphocytes isolated from patients with active lupus nephritis. In conclusion, we demonstrate the major role played by PI3Kα in proliferative glomerulonephritis and show that in this condition, alpelisib acts on both podocytes and the immune system.
- 6 June 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (15)
Open AccessPIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis
Proliferative glomerulonephritis is a severe condition that often leads to kidney failure. There is a significant lack of effective treatment for these disorders. Here, following the identification of a somatic PIK3CA gain-of-function mutation in podocytes of a patient, we demonstrate using multiple genetically engineered mouse models, single-cell RNA sequencing, and spatial transcriptomics the crucial role played by this pathway for proliferative glomerulonephritis development by promoting podocyte proliferation, dedifferentiation, and inflammation. Additionally, we show that alpelisib, a PI3Kα inhibitor, improves glomerular lesions and kidney function in different mouse models of proliferative glomerulonephritis and lupus nephritis by targeting podocytes. Surprisingly, we determined that pharmacological inhibition of PI3Kα affects B and T lymphocyte populations in lupus nephritis mouse models, with a decrease in the production of proinflammatory cytokines, autoantibodies, and glomerular complement deposition, which are all characteristic features of PI3Kδ inhibition, the primary PI3K isoform expressed in lymphocytes. Importantly, PI3Kα inhibition does not impact lymphocyte function under normal conditions. These findings were then confirmed in human lymphocytes isolated from patients with active lupus nephritis. In conclusion, we demonstrate the major role played by PI3Kα in proliferative glomerulonephritis and show that in this condition, alpelisib acts on both podocytes and the immune system.
- Open Access
- 27 February 2024
- Published by S. Karger AG in Nephron
- Vol. 148 (9) , 618-630
Bile Acids and Farnesoid X Receptor in Renal Pathophysiology
Background: Bile acids (BAs) act not only as lipids and lipid-soluble vitamin detergents but also function as signaling molecules, participating in diverse physiological processes. The identification of BA receptors in organs beyond the enterohepatic system, such as the farnesoid X receptor (FXR), has initiated inquiries into their organ-specific functions. Among these organs, the kidney prominently expresses FXR. Summary: This review provides a comprehensive overview of various BA species identified in kidneys and delves into the roles of renal apical and basolateral BA transporters. Furthermore, we explore changes in BAs and their potential implications for various renal diseases, particularly chronic kidney disease. Lastly, we center our discussion on FXR, a key BA receptor in the kidney and a potential therapeutic target for renal diseases, providing current insights into the protective mechanisms associated with FXR agonist treatments. Key Messages: Despite the relatively low concentrations of BAs in the kidney, their presence is noteworthy, with rodents and humans exhibiting distinct renal BA compositions. Renal BA transporters efficiently facilitate either reabsorption into systemic circulation or excretion into the urine. However, adaptive changes in BA transporters are evident during cholestasis. Various renal diseases are accompanied by alterations in BA concentrations and FXR expression. Consequently, the activation of FXR in the kidney could be a promising target for mitigating kidney damage.
- 27 February 2024
- Published by S. Karger AG in Nephron
- Vol. 148 (9) , 618-630
Open AccessBile Acids and Farnesoid X Receptor in Renal Pathophysiology
Background: Bile acids (BAs) act not only as lipids and lipid-soluble vitamin detergents but also function as signaling molecules, participating in diverse physiological processes. The identification of BA receptors in organs beyond the enterohepatic system, such as the farnesoid X receptor (FXR), has initiated inquiries into their organ-specific functions. Among these organs, the kidney prominently expresses FXR. Summary: This review provides a comprehensive overview of various BA species identified in kidneys and delves into the roles of renal apical and basolateral BA transporters. Furthermore, we explore changes in BAs and their potential implications for various renal diseases, particularly chronic kidney disease. Lastly, we center our discussion on FXR, a key BA receptor in the kidney and a potential therapeutic target for renal diseases, providing current insights into the protective mechanisms associated with FXR agonist treatments. Key Messages: Despite the relatively low concentrations of BAs in the kidney, their presence is noteworthy, with rodents and humans exhibiting distinct renal BA compositions. Renal BA transporters efficiently facilitate either reabsorption into systemic circulation or excretion into the urine. However, adaptive changes in BA transporters are evident during cholestasis. Various renal diseases are accompanied by alterations in BA concentrations and FXR expression. Consequently, the activation of FXR in the kidney could be a promising target for mitigating kidney damage.
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#5399 VONAFEXOR AS A NOVEL THERAPY FOR CHRONIC KIDNEY DISEASE
Chronic kidney diseases (CKD) are characterized by the progressive loss of renal function. The molecular mechanisms underlying this progression are still poorly characterized and probably multifactorial. Therefore, there is a real need to expand the very limited number of therapies able to slow down the rate of CKD progression. Recent findings indicate that NR1H4, a druggable nuclear receptor, might play an important role in CKD. The aim of this study was to investigate the benefit of Vonafexor, a novel small molecule and specific NR1H4 agonist in acquired and genetic models of CKD. Two complementary experimental models of CKD (the 75% excision of total renal mass (Subtotal Nephrectomy; Nx) and the Col4a3−/− mice, a model of Alport disease) were studied. NR1H4 and the expression of some of its downstream targets were evaluated by quantitative RT-PCR, western blot and immunohistochemistry. In the Nx model, mice were treated with Vonafexor by daily oral gavage from 5 to 8 weeks after the surgery. The possible beneficial effect was compared to that of Losartan and other NR1H4 agonists. In the Alport model, mice were treated by Vonafexor from 5 to 8 weeks after birth. In both models, group of mice were sacrificed at 5 weeks to evaluate the extent of renal lesions at baseline. Renal lesions were quantified using image J. Renal inflammation, myofibroblast activation and podocyte number were quantified after specific staining. Human biopsies were also studied. RNAseq was performed using Illumina NovaSeq6000. We observed that NR1H4 expression and OSTA and OSTB, two downstream targets of NR1H4, were significantly reduced in remnant kidneys of Nx FVB/N mice compared to sham-operated animals 8 weeks after surgery. Co-localization staining revealed that NR1H4 is mainly expressed in proximal tubules and, to a minor extent, in Henle loops. Renal lesions were already present at 5 weeks in both experimental models. Remarkably, Vonafexor stopped the progression of renal lesions, in terms of glomerulosclerosis and tubular dilatations and, more importantly, induced a regression of interstitial fibrosis 8 weeks after nephrectomy as compared to the 5-week baseline. Lymphocytes and macrophage infiltration, as well as activated myofibroblasts, were also significantly reduced. Similarly, podocyte loss was stopped by Vonafexor treatment. Of note, the beneficial effect of Vonafexor was unique compared to other classes of NR1H4 agonists and also higher than that of Losartan. The same beneficial curative effect was found in Col4a3−/− mice. RT-PCR confirmed the activation of several NR1H4 downstream targets in mice treated with Vonafexor, while RNAseq analysis revealed that Vonafexor impacted the pathological activation of pathways involved in cell cycle, cell signaling and metabolism. These results may be relevant to humans, since NR1H4 expression was significantly reduced in biopsies from patients with CKD of different etiologies as compared to control kidneys. Altogether our results identified in Vonafexor a novel key drug to control CKD. This is consistent with recent results obtained in LIVIFY phase 2 clinical trial in which Vonafexor has already demonstrated beneficial effects on eGFR in NASH patients with mild to moderate CKD.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#5399 VONAFEXOR AS A NOVEL THERAPY FOR CHRONIC KIDNEY DISEASE
Chronic kidney diseases (CKD) are characterized by the progressive loss of renal function. The molecular mechanisms underlying this progression are still poorly characterized and probably multifactorial. Therefore, there is a real need to expand the very limited number of therapies able to slow down the rate of CKD progression. Recent findings indicate that NR1H4, a druggable nuclear receptor, might play an important role in CKD. The aim of this study was to investigate the benefit of Vonafexor, a novel small molecule and specific NR1H4 agonist in acquired and genetic models of CKD. Two complementary experimental models of CKD (the 75% excision of total renal mass (Subtotal Nephrectomy; Nx) and the Col4a3−/− mice, a model of Alport disease) were studied. NR1H4 and the expression of some of its downstream targets were evaluated by quantitative RT-PCR, western blot and immunohistochemistry. In the Nx model, mice were treated with Vonafexor by daily oral gavage from 5 to 8 weeks after the surgery. The possible beneficial effect was compared to that of Losartan and other NR1H4 agonists. In the Alport model, mice were treated by Vonafexor from 5 to 8 weeks after birth. In both models, group of mice were sacrificed at 5 weeks to evaluate the extent of renal lesions at baseline. Renal lesions were quantified using image J. Renal inflammation, myofibroblast activation and podocyte number were quantified after specific staining. Human biopsies were also studied. RNAseq was performed using Illumina NovaSeq6000. We observed that NR1H4 expression and OSTA and OSTB, two downstream targets of NR1H4, were significantly reduced in remnant kidneys of Nx FVB/N mice compared to sham-operated animals 8 weeks after surgery. Co-localization staining revealed that NR1H4 is mainly expressed in proximal tubules and, to a minor extent, in Henle loops. Renal lesions were already present at 5 weeks in both experimental models. Remarkably, Vonafexor stopped the progression of renal lesions, in terms of glomerulosclerosis and tubular dilatations and, more importantly, induced a regression of interstitial fibrosis 8 weeks after nephrectomy as compared to the 5-week baseline. Lymphocytes and macrophage infiltration, as well as activated myofibroblasts, were also significantly reduced. Similarly, podocyte loss was stopped by Vonafexor treatment. Of note, the beneficial effect of Vonafexor was unique compared to other classes of NR1H4 agonists and also higher than that of Losartan. The same beneficial curative effect was found in Col4a3−/− mice. RT-PCR confirmed the activation of several NR1H4 downstream targets in mice treated with Vonafexor, while RNAseq analysis revealed that Vonafexor impacted the pathological activation of pathways involved in cell cycle, cell signaling and metabolism. These results may be relevant to humans, since NR1H4 expression was significantly reduced in biopsies from patients with CKD of different etiologies as compared to control kidneys. Altogether our results identified in Vonafexor a novel key drug to control CKD. This is consistent with recent results obtained in LIVIFY phase 2 clinical trial in which Vonafexor has already demonstrated beneficial effects on eGFR in NASH patients with mild to moderate CKD.
- Open Access
- 6 June 2023
- Published by Elsevier in EBioMedicine
- Vol. 93, 104635
Combining robust urine biomarkers to assess chronic kidney disease progression
- 6 June 2023
- Published by Elsevier in EBioMedicine
- Vol. 93, 104635
Open AccessCombining robust urine biomarkers to assess chronic kidney disease progression